Roth Capital Starts Bionano Genomics (BNGO) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- Copart nears $2B all-cash deal to acquire ACV Auctions - Bloomberg
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
UPDATE: Maxim Group Starts Bionano Genomics (BNGO) at Buy
September 25, 2018 7:41 AM EDT(Updated - September 25, 2018 7:57 AM EDT)
(updated to add analyst comments)
Maxim Group analyst Jason McCarthy initiates coverage on Bionano Genomics (NASDAQ: BNGO) with a Buy rating and a price target of $11.00.
McCarthy highlighted:
We are initiating coverage of Bionano Genomics with a Buy rating and $11 price target. Bionanos Saphyr could be the bridge between next-gen sequencing... More